Founded in 2003, BrainsWay develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a noninvasive neurostimulation platform designed to treat psychiatric and neurological disorders. The company's core offering is its proprietary TMS system, which uses magnetic pulses to stimulate specific brain regions. The platform targets conditions including major depressive disorder, obsessive-compulsive disorder, anxiety, smoking addiction, bipolar disorder, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease.
The company operates primarily as a medical device manufacturer and service provider, generating revenue through sales of its Deep TMS systems and related clinical services to psychiatric hospitals, general hospitals, and medical centers. Its primary customer base comprises physicians and healthcare facilities specializing in psychiatry and neurology.
BrainsWay maintains its headquarters in Jerusalem, Israel, with approximately 120 full-time employees. The company markets its products in the United States, East Asia, and other international markets, with the U.S. representing a significant portion of its revenue base. The company is incorporated in Israel and trades on the Nasdaq exchange.
No 10-K filings found.